Media and News
PharmaNova to Present Poster at Controlled Release Product Development Forum on Poorly Soluble Drugs, January 27-28, 2011, Miami FL.
PharmaNova, Inc. of Victor, NY announced that Dr. Deepak Thassu, Chief Scientific Officer and VP Product Development at PharmaNova will be presenting a poster at the Controlled Release Product Development Forum on Poorly Soluble Drugs in conjunction with 15th Annual Drug Delivery Partnerships, January 27 -28, 2011 at the Doral Golf Resort and Spa, Miami, FL. Dr. Thassu’s poster presentation entitled “Surface-Modified Nanoparticles Enhance Delivery of Poorly Soluble Drugs” reflects the latest advances of PharmaNova’s proprietary NovaSperse℠ nanoparticle technology. Controlled release is a research discipline whose future depends on a thorough understanding of the interactions between the delivery system and the biological or environmental barriers to delivery of active substances. PharmaNova’s NovaSperse℠ technology is based on de novo creation of controlled particle size of varying specificity. NovaSperse℠ provides a solution to client‐owned products and compounds to support new product development or the extended life cycle management of existing products.
CRS is an international organization which serves 3,000 members from more than 50 countries; the annual meeting attracts numerous industry representatives, scientists, academia, and international regulatory agencies.
For more information about the 2011 Product Development Forum, see: http://www.controlledrelease.org/main/meetings/2011ProductDevelopForum.cfm
PharmaNova Inc. is a privately held pharmaceutical company. Our product candidates are derived from the re‐positioning and enhancement of known drugs using our proprietary NovaSperse℠ nanoparticle technology platform. We address low risk, fast to market products in areas of clear medical need and generate revenue from partnering and licensing strategies with commercialization partners and clients worldwide. PharmaNova also conducts contractual formulation development work applying NovaSperse℠ technology to client‐owned products and compounds to support new product development or the extended life cycle management of existing products. PharmaNova has other new product candidates in various stages in its development pipeline. Our focus is on the development of novel, improved nanoparticle formulations of ophthalmic and anti-infective products.
Members of the media wishing to learn more about Pharmanova should contact: Rodney Brown, President. Rodney.Brown@pharmanovaco.com, (585)-413-4721.
« Back to Media
Member of the media wishing to learn more about Pharmanova should contact:
Rafael Larramendi, President | Rafael.firstname.lastname@example.org | (585) 413-4721.